Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Connect Biopharma Holdings (CNTB) Accumulated Depreciation & Amortization (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $704000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 6.67% to $704000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $704000.0 through Dec 2025, up 6.67% year-over-year, with the annual reading at $704000.0 for FY2025, 6.67% up from the prior year.
  • Accumulated Depreciation & Amortization hit $704000.0 in Q4 2025 for Connect Biopharma Holdings, up from $660000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $720000.0 in Q4 2023 to a low of $660000.0 in Q4 2024.
  • Historically, Accumulated Depreciation & Amortization has averaged $694666.7 across 3 years, with a median of $704000.0 in 2025.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: dropped 8.33% in 2024 and later increased 6.67% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $720000.0 in 2023, then fell by 8.33% to $660000.0 in 2024, then increased by 6.67% to $704000.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CNTB at $704000.0 in Q4 2025, $660000.0 in Q4 2024, and $720000.0 in Q4 2023.